USFDA conducts inspection at Cipla’s Indore facility
The United States Food and Drug Administration (USFDA) has conducted a post-approval inspection at Cipla’s Indore facility from May 13 – 17, 2019. The inspection ended with zero observations.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.